Loading clinical trials...
Loading clinical trials...
The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
PepGen Inc
NCT06300307 · Myotonic Dystrophy 1
NCT07136844 · Neuromuscular Diseases, Obesity (Disorder), and more
NCT02398786 · Myotonic Dystrophy, Congenital Myotonic Dystrophy, and more
NCT07008469 · Myotonic Dystrophy Type 1, DM1, and more
NCT06101940 · Myotonic Dystrophy 1
UCI Center for Clinical Research
Irvine, California
Stanford University
Palo Alto, California
Rare Disease Research
Atlanta, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions